Search Results

The LCV+ Version 2 is indicated for use in generating fluoroscopic images of human analomy for cardiology diagnostic interventional procedures. It is intended to replace fluoroscopic images obtained through the image intensifier technology.

The LCV+ Version 2 is designed to perform fluoroscopic x-ray examinations. The detector is comprised of amorphous silicon with a cesium iodide scintillator. The resulting digital image can be sent through a fiber channel link to an acquisition equipment then to a network (using DICOM) for applications such as post-processing, printing, viewing and archiving. LCV+ Version 2 consists of a cardiac monoplane positioner, a vascular table, an X-RAY system and a digital detector.

Here's an analysis of the provided text to extract the acceptance criteria and study details:

1. Table of Acceptance Criteria and Reported Device Performance:

2. Sample Size for Test Set and Data Provenance:

• Sample Size: 31 pairs of patients (implying 31 cases with both digital and image-intensifier recorded images).
• Data Provenance: Not explicitly stated, but the study involved "two (2) hospitals." The type of study (retrospective or prospective) is also not specified.

3. Number of Experts and Qualifications:

• Number of Experts: Six (6) cardiologists.
• Qualifications: "Cardiologists" from two hospitals. No further details on years of experience or specific sub-specialties are provided.

4. Adjudication Method:

• The text states that the cardiologists "compared" the images. It does not describe a formal adjudication method (like 2+1 or 3+1). It seems they individually evaluated the images, and the overall finding was a consensus of "equivalent image capability." There's no mention of a tie-breaking or reconciliation process.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:

• No, a formal MRMC comparative effectiveness study in the sense of measuring improvement in human readers with AI vs. without AI assistance was not done.
• The study described is a comparison of two imaging modalities (digital vs. image-intensifier) to establish equivalence in diagnostic capability, involving multiple readers (6 cardiologists) and multiple cases (31 pairs of patients). However, the device itself is an imaging system, not an AI assisting human readers, so this type of MRMC study would not be applicable here.

6. Standalone (Algorithm Only) Performance:

• Yes, a standalone evaluation was performed implicitly. The study assessed the diagnostic capability of the digital images produced by the LCV+ Version 2 system compared to traditional image-intensifier images. The "device" in question is the imaging system itself, and its performance (producing images with equivalent diagnostic capability) was evaluated directly.

7. Type of Ground Truth Used:

• Expert Consensus/Clinical Equivalence: The ground truth was established by the subjective evaluation and comparison of the diagnostic capabilities of images by six cardiologists. It's essentially a clinical equivalence assessment based on expert opinion. There's no mention of a gold standard like pathology or long-term outcomes data to definitively determine the "true" diagnosis for each case.

8. Sample Size for the Training Set:

• The document does not mention a training set. The LCV+ Version 2 is described as an X-ray imaging system with a digital detector, not a machine learning or AI-based diagnostic algorithm that would typically require a training set. The comparison study described is for validation, not training.

9. How the Ground Truth for the Training Set Was Established:

• Not applicable, as no training set is mentioned for this device.

Ask a specific question about this device

Smart Vessel Analysis (SmartVA) is a software post-processing option for the Advantage Workstation (AW) platform which can be used in the analysis of 3D angiography data. It provides a number of display, measurement and batch filming/archive features and will aid physicians in studying user-selected vessels for stenosis analysis, pre/post stent planning and directional vessel tortuosity visualization.

SmartVA is a software post-processing package for the Advantage Workstation (AW) platform. It is an additional tool for the analysis of 3D angiography data providing a number of display, measurement and batch filming/archive features to study user-selected vessels which include but are not limited to stenosis analysis, pre/post stent planning procedures and directional vessel tortuosity visualization.

The provided document is a 510(k) summary for the GE Smart Vessel Analysis (Smart VA) Option. This type of document is typically submitted to the FDA to demonstrate substantial equivalence to a legally marketed predicate device, rather than to present a full clinical study proving specific performance criteria.

Therefore, the document does not contain the detailed information requested regarding:

• A table of acceptance criteria and reported device performance.
• Sample sizes used for test sets or their provenance.
• Number and qualifications of experts for ground truth.
• Adjudication methods.
• Multi-reader multi-case (MRMC) comparative effectiveness study results.
• Standalone algorithm performance.
• The type of ground truth used.
• Sample size for the training set.
• How ground truth for the training set was established.

Analysis of the document:

The document focuses on establishing substantial equivalence to existing devices (Advantage Windows 3D with Navigator Option and DLX) based on similar functionalities for 3D angiography data analysis. It highlights features like:

• Display, measurement, and batch filming/archive features.
• Assistance in studying user-selected vessels for stenosis analysis, pre/post stent planning, and directional vessel tortuosity visualization.

Instead of presenting performance metrics, the submission relies on:

• Comparison with Predicate: Stating that "The vessel measurements are similar to DLX and the visualization views of the vessel provided are similar to Advantage Windows 3D with Navigator option."
• Risk Management: Mentioning a risk management plan, software development and validation process, and software verification plan to control potential hazards.
• Image Comparability: Concluding that "This product provides images comparable to the predicate devices."

Conclusion:

Based on the provided text, a comprehensive answer to the request regarding acceptance criteria and a study proving those criteria cannot be formulated because the document does not contain this specific information. The 510(k) summary is designed to demonstrate substantial equivalence, not to detail the clinical validation or performance studies that would typically include the requested data points.

Ask a specific question about this device